Dudediligence.

Surrozen, Inc

SRZNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$10.0MSep ’24$655,000Dec ’24$983,000Mar ’25$983,000Jun ’25$983,000Sep ’25$528,000Dec ’25$5.0MMar ’26$5.0MJun ’26
Net income, by quarter
−$1.4MSep ’24−$28.0MDec ’24−$27.0MMar ’25$39.7MJun ’25−$71.6MSep ’25−$183.2MDec ’25−$127.5MMar ’26$50.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$12.5M$0.00$10.7M$3.5M
Operating income−$54.4M−$44.3M−$45.8M−$25.5M−$42.1M
Net income−$54.6M−$36.0M−$43.0M−$63.6M−$242.0M
Operating cash flow−$48.8M−$44.1M−$40.4M−$17.6M−$30.2M
Free cash flow−$50.1M−$44.9M−$40.8M−$17.7M−$30.4M
Cash$33.1M$24.7M$36.0M$34.6M$89.2M
Shares outstanding35.0M2.0M2.1M3.3M9.8M